The legal imperative for treating rare disorders

@inproceedings{Hyry2013TheLI,
  title={The legal imperative for treating rare disorders},
  author={Hanna I. Hyry and Jonathan C. P. Roos and Jeremy Manuel and Timothy Martin Cox},
  booktitle={Orphanet journal of rare diseases},
  year={2013}
}
BACKGROUND Life-saving orphan drugs are some of the most expensive medicines. European Union governments aim to accommodate their provision within stretched healthcare budgets but face pressure to reduce funding of such treatments. Patients struggle to retain or gain access to them as their special status is questioned, causing distress and in some cases, fears of premature death. In the UK and EU reimbursement and pricing model of drugs, and orphan drugs in particular, is being re-evaluated… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 20 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
6 Citations
14 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 14 references

GlaxoSmithKline: Value & Specificity of Rare Diseases

  • M Dunoyer
  • Business Model. Brussels: 6th European Conference…
  • 2012
Highly Influential
6 Excerpts

Assessment of treatment for Gaucher disease ends , ( in Swedish )

  • T Sheldon
  • Competition DG : Pharmaceutical sector inquiry…
  • 2012

General of the Directorate-General for Health and Consumers of the European Commission: Orphan Products and Rare Disease Therapies

  • P TestoriCoggi, Director
  • Brussels: 6th European Conference on Rare…
  • 2012
1 Excerpt

Greek crisis gets under skin of vulnerable

  • A Jack, K Hope
  • Financial Times
  • 2012
1 Excerpt

Why is the press so nasty to NICE ?

  • N Hawkes
  • A new value - based approach to the pricing of…
  • 2011

The tier 4 phenomenon: shifting the high cost of drugs to consumers

  • B Walsh
  • Washington DC: AARP;
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…